Nolte, Kathleen

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","74"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Mensching, Steffen"],["dc.contributor.author","Siegmund, Friederike"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:41:03Z"],["dc.date.available","2019-07-09T11:41:03Z"],["dc.date.issued","2014"],["dc.description.abstract","Background The long-term effects of exercise training (ET) in diastolic dysfunction (DD) and heart failure with preserved ejection fraction (HFpEF) are unknown. The present study compared the long-term effects of ET on exercise capacity, diastolic function, and quality of life (QoL) in patients with DD vs. HFpEF. Methods A total of n=43 patients with asymptomatic DD (n=19) or HFpEF [DD and New York Heart Association (NYHA) ≥II, n=24] and left ventricular ejection fraction ≥50% performed a combined endurance/resistance training over 6months (2–3/week) on top of usual care. Cardiopulmonary exercise testing, echocardiography, and QoL were obtained at baseline and follow-up. Results Patients were 62±8 years old (37% female). In the HFpEF group, 67% of patients were in NYHA class II (33% in NYHA III). Exercise capacity (peak oxygen consumption, peak VO2) differed at baseline (DD 29.2±8.7mL/min/kg vs. HFpEF 17.8±4.6 mL/min/kg; P=0.004). After 6months, peak VO2 increased significantly (P<0.044) to 19.7±5.8 mL/min/kg in the HFpEF group and also in the DD group (to 32.8±8.5mL/min/kg; P<0.002) with no overall difference between the groups (P=0.217). E/e′ ratio (left ventricular filling index) decreased from 12.2±3.5 to 10.1±3.0 (P<0.002) in patients with HFpEFand also in patients with DD (10.7±3.1 vs. 9.5±2.3; P=0.03; difference between groups P=0.210). In contrast, left atrial volume index decreased in the HFpEF group (P<0.001) but remained stable within the DD group (difference between groups P=0.015). After 6 months, physical QoL (Minnesota living with heart failure Questionnaire, 36-item short form health survey), general health perception, and 9-item patient health questionnaire score only improved in HFpEF (P<0.05). In contrast, vitality improved in both groups (difference between groups P=0.708). Conclusion A structured 6 months ET programme effectively improves exercise capacity and diastolic function in patients with DD and overt HFpEF. Therefore, controlled lifestylemodification with physical activity is effective both in DD and HFpEF."],["dc.identifier.doi","10.1002/ehf2.12007"],["dc.identifier.fs","610857"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11651"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58349"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1879-0844"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.contributor.author","Bueren, F. To"],["dc.contributor.author","Nolte, K."],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Edelmann, F."],["dc.date.accessioned","2018-11-07T09:57:28Z"],["dc.date.available","2018-11-07T09:57:28Z"],["dc.date.issued","2015"],["dc.format.extent","420"],["dc.identifier.isi","000366200403599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37164"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.title","Combination of neurohormones and clinical signs and symptoms to detect a left ventricular dysfunction"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Nolte, K. Kathleen"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Platschek, L."],["dc.contributor.author","Holzendorf, V."],["dc.contributor.author","Gelbrich, Goetz"],["dc.contributor.author","Duengen, H-D"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Edelmann, F."],["dc.date.accessioned","2018-11-07T09:57:25Z"],["dc.date.available","2018-11-07T09:57:25Z"],["dc.date.issued","2015"],["dc.format.extent","281"],["dc.identifier.isi","000366200403095"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37153"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.title","Vitamin D deficiency and the prognosis of patients suffering from diastolic dysfunction or heart failure with preserved ejection fraction"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Morris, Daniel"],["dc.contributor.author","Pieske-Kraigher, Elisabeth"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.date.accessioned","2018-04-23T11:48:12Z"],["dc.date.available","2018-04-23T11:48:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Heart failure with preserved ejection fraction (HFpEF) is a common disease with high incidence and increasing prevalence. Patients suffer from functional limitation, poor health‐related quality of life, and reduced prognosis. A pilot study in a smaller group of HFpEF patients showed that structured, supervised exercise training (ET) improves maximal exercise capacity, diastolic function, and physical quality of life. However, the long‐term effects of ET on patient‐related outcomes remain unclear in HFpEF. The primary objective of the Exercise training in Diastolic Heart Failure (Ex‐DHF) trial is to investigate whether a 12 month supervised ET can improve a clinically meaningful composite outcome score in HFpEF patients. Components of the outcome score are all‐cause mortality, hospitalizations, NYHA functional class, global self‐rated health, maximal exercise capacity, and diastolic function. After undergoing baseline assessments to determine whether ET can be performed safely, 320 patients at 11 trial sites with stable HFpEF are randomized 1:1 to supervised ET in addition to usual care or to usual care alone. Patients randomized to ET perform supervised endurance/resistance ET (3 times/week at a certified training centre) for 12 months. At baseline and during follow‐up, anthropometry, echocardiography, cardiopulmonary exercise testing, and health‐related quality of life evaluation are performed. Blood samples are collected to examine various biomarkers. Overall physical activity, training sessions, and adherence are monitored and documented throughout the study using patient diaries, heart rate monitors, and accelerometers. The Ex‐DHF trial is the first multicentre trial to assess the long‐term effects of a supervised ET programme on different outcome measures in patients with HFpEF."],["dc.identifier.doi","10.1002/ejhf.862"],["dc.identifier.gro","3142337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13472"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","1388-9842"],["dc.title","Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E120"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","E128"],["dc.bibliographiccitation.volume","140"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Gabriel, F."],["dc.contributor.author","Stahrenberg, Raoul"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2017-09-07T11:43:47Z"],["dc.date.available","2017-09-07T11:43:47Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1055/s-0041-102543"],["dc.identifier.gro","3141891"],["dc.identifier.isi","000357031900001"],["dc.identifier.pmid","26115140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2222"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.eissn","1439-4413"],["dc.relation.issn","0012-0472"],["dc.title","GDF-15, MRproADM, CTproET1 and CTproAVP in Patients with asymptomatic diastolic Dysfunction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Platschek, Lars"],["dc.contributor.author","Holzendorf, Volker"],["dc.contributor.author","Pilz, Stefan"],["dc.contributor.author","Tomaschitz, Andreas"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Angermann, Christiane E"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:50:12Z"],["dc.date.available","2019-07-09T11:50:12Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: Vitamin D deficiency is prevalent in heart failure (HF), but its relevance in early stages of heart failure with preserved ejection fraction (HFpEF) is unknown. We tested the association of 25-hydroxyvitamin D [25(OH)D] serum levels with mortality, hospitalizations, cardiovascular risk factors, and echocardiographic parameters in patients with asymptomatic diastolic dysfunction (DD) or newly diagnosed HFpEF. METHODS AND RESULTS: We measured 25(OH)D serum levels in outpatients with risk factors for DD or history of HF derived from the DIAST-CHF study. Participants were comprehensively phenotyped including physical examination, echocardiography, and 6 min walk test and were followed up to 5 years. Quality of life was evaluated by the Short Form 36 (SF-36) questionnaire. We included 787 patients with available 25(OH)D levels. Median 25(OH)D levels were 13.1 ng/mL, mean E/e' medial was 13.2, and mean left ventricular ejection fraction was 59.1%. Only 9% (n = 73) showed a left ventricular ejection fraction <50%. Fifteen per cent (n = 119) of the recruited participants had symptomatic HFpEF. At baseline, participants with 25(OH)D levels in the lowest tertile (≤10.9 ng/L; n = 263) were older, more often symptomatic (oedema and fatigue, all P ≤ 0.002) and had worse cardiac [higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and left atrial volume index, both P ≤ 0.023], renal (lower glomerular filtration rate, P = 0.012), metabolic (higher uric acid levels, P < 0.001), and functional (reduced exercise capacity, 6 min walk distance, and SF-36 physical functioning score, all P < 0.001) parameters. Increased NT-proBNP, uric acid, and left atrial volume index and decreased SF-36 physical functioning scores were independently associated with lower 25(OH)D levels. There was a higher risk for lower 25(OH)D levels in association with HF, DD, and atrial fibrillation (all P ≤ 0.004), which remained significant after adjusting for age. Lower 25(OH)D levels (per 10 ng/mL decrease) tended to be associated with higher 5 year mortality, P = 0.05, hazard ratio (HR) 1.55 [1.00; 2.42]. Furthermore, lower 25(OH)D levels (per 10 ng/mL decrease) were related to an increased rate of cardiovascular hospitalizations, P = 0.023, HR = 1.74 [1.08; 2.80], and remained significant after adjusting for age, P = 0.046, HR = 1.63 [1.01; 2.64], baseline NT-proBNP, P = 0.048, HR = 1.62 [1.01; 2.61], and other selected baseline characteristics and co-morbidities, P = 0.043, HR = 3.60 [1.04; 12.43]. CONCLUSIONS: Lower 25(OH)D levels were associated with reduced functional capacity in patients with DD or HFpEF and were significantly predictive for an increased rate of cardiovascular hospitalizations, also after adjusting for age, NT-proBNP, and selected baseline characteristics and co-morbidities."],["dc.identifier.doi","10.1002/ehf2.12413"],["dc.identifier.pmid","30784226"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15880"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59721"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0136739"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Meyer, Thomas"],["dc.contributor.author","Chavanon, Mira-Lynn"],["dc.contributor.author","Herrrmann-Lingen, Christoph"],["dc.contributor.author","Roggenthien, Maren"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Edelmann, Frank T."],["dc.date.accessioned","2018-11-07T09:53:06Z"],["dc.date.available","2018-11-07T09:53:06Z"],["dc.date.issued","2015"],["dc.description.abstract","Background The role of endothelin-1 (ET-1) in the neurobiology of anxiety is unknown, therefore, we assessed in the observational multicenter DIAST-CHF study whether the C-terminal ET-1 precursor fragment (CT-proET-1) is linked to anxiety. Methods Plasma concentrations of CT-proET-1 were measured in a total of 1,410 patients presenting with cardiovascular risk factors (mean age 66.91 +/- 8.2 years, 49.3% males, mean left ventricular ejection fraction 60.0 +/- 8.2%) who had completed the Hospital Anxiety and Depression Scale (HADS) questionnaire. Results Among the total study cohort (n = 1,410), there were 118 subjects (8.4%) with an HADS anxiety score above the cut-off level of 11 suggestive of clinically relevant anxiety. Plasma CT-proET-1 levels were significantly lower in the group of anxious patients as compared to non-anxious patients (p = 0.013). In regression models adjusted for sex, age, systolic blood pressure, and diameters of left atrium and ventricle, plasma CT-proET-1 was again linked to anxiety (Exp(beta) = 0.247, 95%-confidence interval [95%-CI] = 0.067-0.914, p = 0.036). Given the high prevalence of depressive disorders in anxious patients, we additionally included the HADS depression score as an independent variable in the models and found that CT-proET-1 remained a significant predictor of anxiety, independent of comorbid depression (Exp(beta) = 0.114, 95%-CI = 0.023-0.566, p = 0.008). Conclusions Our data from a population-based study in outpatients with cardiovascular risk factors revealed that circulating CT-proET-1 levels are negatively associated with anxiety. Further investigations are required to clarify the putative anxiolytic effect of ET-1 or its precursor molecules in humans and to decipher its mechanistic pathways."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1371/journal.pone.0136739"],["dc.identifier.isi","000360435500031"],["dc.identifier.pmid","26322793"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12085"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36258"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","62"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Bartels, Inke"],["dc.contributor.author","Münch, Marlene"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Tschöpe, Carsten"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2018-04-23T11:48:01Z"],["dc.date.available","2018-04-23T11:48:01Z"],["dc.date.issued","2018"],["dc.description.abstract","Aims Heart failure with preserved ejection fraction (HFpEF) remains a common condition with no pharmacological treatment. Physical activity (PA) improves symptoms and quality of life (QoL), but no clear recommendations exist on PA in HFpEF patients. We investigated the association of PA (amount/intensity) on clinical phenotype in HFpEF. Methods and results The Aldosterone in Diastolic Heart Failure trial investigated spironolactone vs. placebo in stable HFpEF patients. At baseline, all patients underwent detailed phenotypization including echocardiography, cardiopulmonary exercise testing, 6 minute walking test (6MWT), and QoL assessment (36‐item Short‐Form questionnaire). PA was assessed by a self‐report questionnaire, classified in metabolic equivalents of task (MET) and analysed with regard to exercise capacity, diastolic function, and QoL. Four hundred twenty‐two patients (52% women, age 67 ± 8 years, New York Heart Association II and III) were classified by weekly MET hours into a low (<70), middle (70–140), or high (>140) level of PA. Total PA correlated positively with 6MWT distance (r = 0.17; P = 0.002) and physical function of QoL (r = 0.10; P = 0.05), but not with peak oxygen uptake (peakVO2). In contrast, both 6MWT distance and peakVO2 were significantly higher in patients who performed high‐intensity PA for >8 h/week (P < 0.001, P = 0.02, respectively). Time of high‐intensity PA was related to higher 6MWT distance (r = 0.21, P < 0.001), peakVO2, and better physical function of QoL (both r = 0.13, P = 0.01), whereas low‐intensity PA did not show significant associations. Interestingly, PA was not related to any measure of diastolic function. Conclusions A higher amount of PA is related to higher submaximal exercise capacity and physical function of QoL. Regarding maximal exercise capacity, only high‐intensity PA showed significant association in HFpEF patients."],["dc.identifier.doi","10.1002/ehf2.12227"],["dc.identifier.gro","3142318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13451"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","2055-5822"],["dc.title","Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","ehf2.14131"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.contributor.author","Hashemi, Djawid"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Trippel, Tobias D."],["dc.contributor.author","Petutschnigg, Johannes"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann‐Lingen, Christoph"],["dc.contributor.author","Feuerstein, Anna"],["dc.contributor.author","Langhammer, Romy"],["dc.contributor.author","Tschöpe, Carsten"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2022-10-04T10:21:24Z"],["dc.date.available","2022-10-04T10:21:24Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1002/ehf2.14131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114398"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","2055-5822"],["dc.relation.issn","2055-5822"],["dc.title","Evaluation of the HFA‐PEFF Score: results from the prospective DIAST‐CHF cohort"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","214"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","223"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Holzendorf, Volker"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Schmidt, Albrecht G."],["dc.contributor.author","Kraigher-Krainer, Elisabeth"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Unkelbach, Ines"],["dc.contributor.author","Duengen, Hans-Dirk"],["dc.contributor.author","Tschoepe, Carsten"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Stough, Wendy Gattis"],["dc.contributor.author","Pieske, Burkert M."],["dc.date.accessioned","2017-09-07T11:44:38Z"],["dc.date.available","2017-09-07T11:44:38Z"],["dc.date.issued","2015"],["dc.description.abstract","AimsGalectin-3 is a marker of myocardial fibrosis and mediates aldosterone-induced cardiovascular inflammation and fibrosis. Characteristics of galectin-3 and its response to spironolactone have not been evaluated in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to determine the association between galectin-3 levels and patient characteristics in HFpEF; to evaluate the interaction between spironolactone and galectin-3 levels; and to assess the association between galectin-3 and clinical outcomes. Methods and resultsAldo-DHF investigated spironolactone 25mg once daily vs. placebo for 12 months in patients with NYHA class II-III, LVEF 50%, gradeI diastolic dysfunction, and peakVO(2)25mL/kg/min. Galectin-3 levels were obtained at baseline, and at 6 and 12 months. The association between baseline galectin-3, change in galectin-3, and all-cause death or hospitalization was evaluated, and the interaction between galectin-3 and treatment was assessed. Median baseline galectin-3 was 12.1ng/mL. After multivariable adjustment, baseline galectin-3 inversely correlated with peak VO2 (P=0.021)(,) 6min walk distance (P=0.002), and Short Form 36 (SF-36) physical functioning (P=0.001), and directly correlated with NYHA class (P=0.007). Baseline NT-proBNP correlated with E/e' velocity ratio (P 0.001), left atrial volume index (P<0.001), and LV mass index (P=0.009). Increasing galectin-3 at 6 or 12 months was associated with all-cause death or hospitalization independent of treatment arm [hazard ratio (HR) 3.319, 95% confidence interval (CI) 1.214-9.07, P=0.019] and NT-proBNP (HR 3.127, 95% CI 1.144-8.549, P=0.026). Spironolactone did not influence galectin-3 levels. ConclusionGalectin-3 levels are modestly elevated in patients with stable HFpEF and relate to functional performance and quality of life. Increasing galectin-3 was associated with worse outcome, independent of treatment or NT-proBNP."],["dc.identifier.doi","10.1002/ejhf.203"],["dc.identifier.gro","3141963"],["dc.identifier.isi","000349675200016"],["dc.identifier.pmid","25418979"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11677"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3024"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]